INT210064

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.31
First Reported 2007
Last Reported 2008
Negated 1
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 1.44
Pain Relevance 0.54

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (SH3GL3) endosome (SH3GL3) signal transduction (SH3GL3)
cytoplasm (SH3GL3)
Anatomy Link Frequency
endothelium 2
SH3GL3 (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain score 7 97.60 Very High Very High Very High
Pain 20 88.40 High High
cva 8 56.64 Quite High
headache 1 26.68 Quite Low
Neuropathic pain 1 8.00 Low Low
Central nervous system 6 5.00 Very Low Very Low Very Low
fibrosis 6 5.00 Very Low Very Low Very Low
imagery 6 5.00 Very Low Very Low Very Low
aspirin 2 5.00 Very Low Very Low Very Low
ischemia 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Fabry Disease 80 99.40 Very High Very High Very High
Pain 27 97.32 Very High Very High Very High
Disease 51 88.80 High High
Hypohidrosis 6 80.64 Quite High
Diarrhoea 3 79.20 Quite High
Renal Disease 50 79.12 Quite High
Neurologic Manifestations 2 60.80 Quite High
Disorders Of Creatine Metabolism 6 59.92 Quite High
Death 7 58.16 Quite High
Cv General 3 Under Development 6 56.64 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Urinary excretion of GL-3 has not been reduced except in patient 4, although his renal function has remained stable during ERT.
Neg (except) Negative_regulation (reduced) of Localization (excretion) of GL-3
1) Confidence 0.31 Published 2008 Journal Journal of Korean Medical Science Section Body Doc Link PMC2526436 Disease Relevance 0.89 Pain Relevance 0.27
The overall composite score for microvascular endothelial GL-3 accumulation decreased from 4.9 ± 1.5 at baseline to 0.7 ± 0.8 at week 20 (85.7% decrease).
Negative_regulation (decreased) of Localization (accumulation) of GL-3
2) Confidence 0.10 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0.10 Pain Relevance 0.10
The first placebo controlled trial with agalsidase beta focused mainly on surrogate endpoints, including clearance of GL-3 from renal endothelium as well as a reduction in GL-3 accumulation in the heart, skin and plasma [6].
Negative_regulation (reduction) of Localization (clearance) of GL-3 in endothelium
3) Confidence 0.03 Published 2007 Journal PLoS ONE Section Body Doc Link PMC1913555 Disease Relevance 0.45 Pain Relevance 0.17

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox